Compare KSS & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSS | VCEL |
|---|---|---|
| Founded | 1962 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 1995 | 1996 |
| Metric | KSS | VCEL |
|---|---|---|
| Price | $22.04 | $41.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $18.88 | ★ $59.71 |
| AVG Volume (30 Days) | ★ 3.5M | 504.6K |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 142.86 | 60.00 |
| EPS | ★ 1.18 | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $21.71 |
| Revenue Next Year | $0.04 | $16.86 |
| P/E Ratio | $17.92 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $11.38 | $28.95 |
| 52 Week High | $25.22 | $49.32 |
| Indicator | KSS | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 75.31 | 54.13 |
| Support Level | $16.19 | $37.78 |
| Resistance Level | N/A | $41.21 |
| Average True Range (ATR) | 0.89 | 1.23 |
| MACD | 0.33 | 0.17 |
| Stochastic Oscillator | 99.32 | 84.90 |
Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.